Visual Field Progression and RNFL Change After PreserFlo MicroShunt Implantation

Launched by KLINIKUM KLAGENFURT AM WÖRTHERSEE · Dec 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a new surgical procedure called the PreserFlo MicroShunt for patients with glaucoma. Glaucoma is a condition that can damage the optic nerve in the eye, often due to high eye pressure, leading to vision loss. The goal of this trial is to see how well the PreserFlo MicroShunt can lower eye pressure and improve or maintain vision over time, compared to traditional surgery methods. The researchers will check both the health of the eye's structure and how well patients can see after the procedure.

To participate in this study, individuals should be between 18 and 80 years old and have glaucoma that is not well controlled with medication. This includes types of glaucoma such as primary open-angle glaucoma and normal tension glaucoma. However, people who have previously had glaucoma surgery or have very poor vision would not be eligible. Participants can expect close monitoring of their eye pressure and vision over the course of the study, helping doctors understand how effective the new treatment is. Overall, this trial aims to provide valuable insights into a potentially safer surgical option for managing glaucoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with insufficient eye pressure control despite IOP (intraocular pressure)-lowering therapy
• • Diagnosis of POAG (primary open angle glaucoma)
• • Diagnosis of PEG (pseudoexfoliation glaucoma)
• • Diagnosis of PDG (pigment dispersion glaucoma)
• • Diagnosis of NTG (normal tension glaucoma)
• • Agreement of patients to participate in the study
• Exclusion Criteria:
• • Previous glaucoma surgery
• • Visual acuity of Nulla Lux
• • Poor general condition
• • Pregnancy
• • Exudative macular degeneration